BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Alkem Laboratories Ltd. delivered better-than-expected Q2 FY21 performance led by domestic formulations and lower opex.
The U.S. generics segment has been largely steady due to less launches in Q2 FY21.
The company remains vigilant of sales outlook and has subsequently calibrated operational cost, particularly in the domestic formulations segment.
We have tweaked our earning per share estimates for FY21/FY22E to factor in continued benefit of lower operating cost in FY21 and higher tax rate for FY22E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR